Joseph W Kim1, Yusuke Tomita, Jane Trepel, Andrea B Apolo. 1. aProstate and Urologic Cancers Program, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut bDevelopmental Therapeutics Branch cGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Inhibition of immune escape mechanisms, such as the programed death-ligand 1 pathway, has demonstrated rapid, durable responses in multiple tumor types, including advanced urothelial carcinoma. This review discusses emerging immunotherapies for urothelial carcinoma in various stages of clinical development. RECENT FINDINGS: Urothelial carcinoma has a high mutational burden, which may increase the number of tumor antigens and potentially enhance the ability of the immune system to recognize tumor cells as foreign. However, urothelial carcinoma can evade the immune system by downregulating tumor-antigen presentation, upregulating various immune checkpoints, and inactivating cytotoxic T cells. Immunotherapies for urothelial carcinoma target each of these steps to restore immune-mediated cytotoxicity. Many of these agents are in clinical trials for urothelial carcinoma. SUMMARY: Immunotherapies are active in urothelial carcinoma, but only in a fraction of patients, implying the presence of persistent immune escape. Identifying the mechanisms of immune escape and developing rational combinatorial regimens may make the benefit of immunotherapy accessible to a broader population.
PURPOSE OF REVIEW: Inhibition of immune escape mechanisms, such as the programed death-ligand 1 pathway, has demonstrated rapid, durable responses in multiple tumor types, including advanced urothelial carcinoma. This review discusses emerging immunotherapies for urothelial carcinoma in various stages of clinical development. RECENT FINDINGS:Urothelial carcinoma has a high mutational burden, which may increase the number of tumor antigens and potentially enhance the ability of the immune system to recognize tumor cells as foreign. However, urothelial carcinoma can evade the immune system by downregulating tumor-antigen presentation, upregulating various immune checkpoints, and inactivating cytotoxic T cells. Immunotherapies for urothelial carcinoma target each of these steps to restore immune-mediated cytotoxicity. Many of these agents are in clinical trials for urothelial carcinoma. SUMMARY: Immunotherapies are active in urothelial carcinoma, but only in a fraction of patients, implying the presence of persistent immune escape. Identifying the mechanisms of immune escape and developing rational combinatorial regimens may make the benefit of immunotherapy accessible to a broader population.
Authors: Mahsa Mohebtash; Kwong-Yok Tsang; Ravi A Madan; Ngar-Yee Huen; Diane J Poole; Caroline Jochems; Jacquin Jones; Theresa Ferrara; Christopher R Heery; Philip M Arlen; Seth M Steinberg; Mary Pazdur; Myrna Rauckhorst; Elizabeth C Jones; William L Dahut; Jeffrey Schlom; James L Gulley Journal: Clin Cancer Res Date: 2011-11-08 Impact factor: 12.531
Authors: Paul F Robbins; Richard A Morgan; Steven A Feldman; James C Yang; Richard M Sherry; Mark E Dudley; John R Wunderlich; Azam V Nahvi; Lee J Helman; Crystal L Mackall; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Mark Raffeld; Chyi-Chia Richard Lee; Catherine L Levy; Yong F Li; Mona El-Gamil; Susan L Schwarz; Carolyn Laurencot; Steven A Rosenberg Journal: J Clin Oncol Date: 2011-01-31 Impact factor: 44.544
Authors: James L Gulley; Philip M Arlen; Ravi A Madan; Kwong-Yok Tsang; Mary P Pazdur; Lisa Skarupa; Jacquin L Jones; Diane J Poole; Jack P Higgins; James W Hodge; Vittore Cereda; Matteo Vergati; Seth M Steinberg; Susan Halabi; Elizabeth Jones; Clara Chen; Howard Parnes; John J Wright; William L Dahut; Jeffrey Schlom Journal: Cancer Immunol Immunother Date: 2009-11-05 Impact factor: 6.968
Authors: Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245
Authors: E Xylinas; B D Robinson; L A Kluth; B G Volkmer; R Hautmann; R Küfer; M Zerbib; E Kwon; R H Thompson; S A Boorjian; S F Shariat Journal: Eur J Surg Oncol Date: 2013-09-18 Impact factor: 4.424
Authors: Farhad Fakhrejahani; Yusuke Tomita; Agnes Maj-Hes; Jane B Trepel; Maria De Santis; Andrea B Apolo Journal: Curr Opin Urol Date: 2015-11 Impact factor: 2.309
Authors: Kim E M van Kessel; Tahlita C M Zuiverloon; Arnout R Alberts; Joost L Boormans; Ellen C Zwarthoff Journal: Nat Rev Urol Date: 2015-09-22 Impact factor: 14.432
Authors: Randy F Sweis; Stefani Spranger; Riyue Bao; Gladell P Paner; Walter M Stadler; Gary Steinberg; Thomas F Gajewski Journal: Cancer Immunol Res Date: 2016-05-17 Impact factor: 11.151